<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871479</url>
  </required_header>
  <id_info>
    <org_study_id>SAN007-02</org_study_id>
    <nct_id>NCT02871479</nct_id>
  </id_info>
  <brief_title>A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santalis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinDatrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Dermatology and Laser Specialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trials of Texas, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Progressive Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Dermatology Partners Bryan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Santalis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and
      efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment
      regimen when administered daily for up to 28 days to patients at least 18 years of age, with
      atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will enter the Screening Period once the informed consent/ascent and photographic
      consent process has been completed. Subjects with a total body surface area (BSA) of ≥2% and
      ≤ 15% atopic dermatitis involvement, in the treatable areas, and who meet all of the
      inclusion and none of the exclusion criteria will be enrolled.

      Once subject eligibility is confirmed and the screening procedures completed, the subject
      will start the Treatment Period of the study. All enrolled subjects will receive either 5%
      SAN007 cream or placebo cream (randomized in a 2:1 ratio) OR 10% SAN007 cream or placebo
      cream (randomized in a 2:1 ratio) with the first dose applied at Visit 1 Baseline. Subjects
      will be instructed on how to apply the study medication twice daily for 28 days. Subjects
      will return to the clinic on Study Days 7,14 and 28 for study-related assessments. Subjects
      will receive a telephone contact from the site, on Study Days 21 and 35.

      Safety will be assessed by evaluating adverse events (AEs) with respect to severity,
      duration, and relationship to study drug.

      In addition, cutaneous tolerability will be evaluated at each visit. Tolerability evaluation
      will be based on subjects reporting discomfort during or immediately following application of
      SAN007. This will also be recorded as an AE. The study exclusion areas are not to be included
      in this evaluation.

      Efficacy will be assessed at each study visit through the completion of the IGA, EASI and BSA
      calculation.

      During the active treatment period, subjects will return to the study site according to the
      study schedule for interim assessments and recording of concomitant medication and adverse
      events (AEs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Have a ≥ 50% Reduction in the Eczema Area and Severity Index (EASI) Score</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects who have a ≥ 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. Minimum value is a 0 and a maximum value is 72. Higher score denoting worse than a lower score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>SAN007 5% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A cream containing 5% East Indian sandalwood oil (EISO).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The vehicle cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAN007 10% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A cream containing 10% East Indian Sandalwood Oil (EISO).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN007 5% cream</intervention_name>
    <description>5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
    <arm_group_label>SAN007 5% cream</arm_group_label>
    <other_name>Albuterpenoids</other_name>
    <other_name>East Indian sandalwood oil (EISO)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo cream containing the same components as the vehicle for the active intervention arm</description>
    <arm_group_label>Placebo cream</arm_group_label>
    <other_name>vehicle cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN007 10% cream</intervention_name>
    <description>10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
    <arm_group_label>SAN007 10% cream</arm_group_label>
    <other_name>Albuterpenoids</other_name>
    <other_name>East Indian Sandalwood Oil (EISO)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be included in the trial if they meet all of the following criteria:

               1. Are at least 18 years of age

               2. Have atopic dermatitis, as determined by an EASI score of ≥5 and ≤50 (Hanifin,
                  2001)

               3. Total treatment area(s) of atopic dermatitis involvement ≥2% and ≤15% today
                  surface area (BSA).

               4. Have atopic dermatitis that has been clinically stable for ≥ 30-days prior to the
                  Screening Visit.

               5. Are able to obtain written informed consent/ascent in a manner approved by the
                  Institutional Review Board and comply with the requirements of the study.

               6. Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics
                  or creams, other than those issued as part of the study, on the target treatment
                  areas during the treatment period.

               7. Are free of any systemic or dermatologic disorder, which, in the opinion of the
                  investigator, will interfere with the study results or increase the risk of
                  adverse events.

               8. Are willing to refrain from exposure to artificial ultraviolet radiation for the
                  duration of the study.

               9. Are willing to cover target treatment areas to avoid exposure to natural
                  ultraviolet radiation for the duration of the study.

              10. If female of childbearing potential, must be willing to practice an acceptable
                  form of birth control for the duration of the study. i.e. barrier method, hormone
                  or intrauterine device.

              11. Are willing to avoid participation in any other interventional clinical trial for
                  the duration of this study.

              12. Are willing to refrain from treating areas that are not in the defined treatment
                  area(s), which will be excluded from the IGA assessments and BSA calculation.
                  These areas are as follows: head, neck, soles of feet, palms of hands, axillae,
                  or intertriginous areas.

        Exclusion Criteria:

          -  Subjects will be excluded from the trial if they meet any of the following criteria:

               1. Have a sibling or immediate family member already participating in this trial.

               2. Currently requires and/or, in the 30 days prior to Screening, has required
                  topical use of a medium or high potency steroid (i.e. &gt;1%)

               3. Atopic dermatitis that, in the opinion of the investigator, is likely to stem
                  from an allergic reaction. (i.e. contact dermatitis)

               4. Have &lt;2% or &gt;15% total BSA of atopic dermatitis involvement in the target
                  treatment area(s).

               5. Have participated in any interventional clinical trial in the previous 30 days to
                  the screening visit.

               6. Have a known sensitivity to any of the constituents of the test product including
                  sensitivities to sandalwood oil, fragrances or any member of the Compositae
                  family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).

               7. Have received phototherapy within the 60 days prior to Screening.

               8. Have received any systemic medication for atopic dermatitis in the past 2 months
                  that would interfere with the evaluation of atopic dermatitis (excluding
                  antihistamines or leukotriene inhibitors).

               9. Have a present condition or abnormality that in the opinion of the Investigator
                  would compromise the safety of the patient or the quality of the data.

              10. Are pregnant, breast-feeding or plan to become pregnant at any point for the
                  duration of the trial.

              11. Are not willing to practice an approved form of birth control while on the study
                  drug for the duration of the trial. i.e. barrier method, hormone or intrauterine
                  device.

              12. Have been treated, with prescription medication for atopic dermatitis, within 60
                  days prior to the Baseline visit.

              13. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell
                  carcinoma, in the last 5 years,or any other confounding skin condition.

              14. Have undergone treatments with topical atopic dermatitis drug products, other
                  than retinoids or corticosteroids, within 14 days prior to the Baseline Visit,
                  and for therapy containing corticosteroids or retinoids within 28 days prior to
                  Baseline Visit.

              15. Have open sores or open lesions in the treatment area(s).

              16. Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol
                  or illegal drug/substance abuse in the past 2 years.

              17. Require greater than 2.0 mg/day inhaled or intranasal corticosteroids.

              18. Have an active infection of any kind at Visit 1 (Baseline)

              19. Have an occupation that requires ≥50% of time be spent outdoors, where prolonged
                  exposure to ultraviolet radiation is unavoidable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Browning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Dermatology and Laser Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Sudies Pharmaceutical</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <results_first_submitted>April 11, 2019</results_first_submitted>
  <results_first_submitted_qc>May 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02871479/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02871479/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SAN007 5% Cream</title>
          <description>A cream containing 5% East Indian sandalwood oil (EISO).
SAN007 5% cream: 5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Cream</title>
          <description>The vehicle cream
Placebo: A placebo cream containing the same components as the vehicle for the active intervention arm</description>
        </group>
        <group group_id="P3">
          <title>SAN007 10% Cream</title>
          <description>A cream containing 10% East Indian Sandalwood Oil (EISO).
SAN007 10% cream: 10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SAN007 5% Cream</title>
          <description>A cream containing 5% East Indian sandalwood oil (EISO).
SAN007 5% cream: 5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Cream</title>
          <description>The vehicle cream
Placebo: A placebo cream containing the same components as the vehicle for the active intervention arm</description>
        </group>
        <group group_id="B3">
          <title>SAN007 10% Cream</title>
          <description>A cream containing 10% East Indian Sandalwood Oil (EISO).
SAN007 10% cream: 10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="15.59"/>
                    <measurement group_id="B2" value="37.0" spread="13.36"/>
                    <measurement group_id="B3" value="29.6" spread="10.4"/>
                    <measurement group_id="B4" value="35.3" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline EASI score</title>
          <description>EASI score is used to measure the severity and extent of eczema. The index is applied to four body regions.The intensity of eczema and the percentage of the affected area are calculated for each region. The intensity of eczema is rated on a 4-point scale of 0-3.
The four intensity scores are added up for each of the four regions to give subtotal. Each subtotal is multiplied by the body surface area represented by that region The % area affected is evaluated in 4 regions of the body.
Each of the body area scores are multiplied by the area affected:
EASI= C1 + C2 + C3 + C4.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.45" spread="3.51"/>
                    <measurement group_id="B2" value="6.28" spread="4.128"/>
                    <measurement group_id="B3" value="7.41" spread="5.73"/>
                    <measurement group_id="B4" value="6.54" spread="4.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.</description>
        <time_frame>28 days</time_frame>
        <population>The FAS group was used for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>SAN007 5% Cream</title>
            <description>A cream containing 5% East Indian sandalwood oil (EISO).
SAN007 5% cream: 5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cream</title>
            <description>The vehicle cream
Placebo: A placebo cream containing the same components as the vehicle for the active intervention arm</description>
          </group>
          <group group_id="O3">
            <title>SAN007 10% Cream</title>
            <description>A cream containing 10% East Indian Sandalwood Oil (EISO).
SAN007 10% cream: 10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.</description>
          <population>The FAS group was used for this outcome measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Have a ≥ 50% Reduction in the Eczema Area and Severity Index (EASI) Score</title>
        <description>Percentage of subjects who have a ≥ 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. Minimum value is a 0 and a maximum value is 72. Higher score denoting worse than a lower score.</description>
        <time_frame>28 days</time_frame>
        <population>The FAS group was used for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>SAN007 5% Cream</title>
            <description>A cream containing 5% East Indian sandalwood oil (EISO).
SAN007 5% cream: 5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cream</title>
            <description>The vehicle cream
Placebo: A placebo cream containing the same components as the vehicle for the active intervention arm</description>
          </group>
          <group group_id="O3">
            <title>SAN007 10% Cream</title>
            <description>A cream containing 10% East Indian Sandalwood Oil (EISO).
SAN007 10% cream: 10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have a ≥ 50% Reduction in the Eczema Area and Severity Index (EASI) Score</title>
          <description>Percentage of subjects who have a ≥ 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. Minimum value is a 0 and a maximum value is 72. Higher score denoting worse than a lower score.</description>
          <population>The FAS group was used for this outcome measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE's were observed over the course of the treatment period, which was 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SAN007 5% Cream</title>
          <description>A cream containing 5% East Indian sandalwood oil (EISO).
SAN007 5% cream: 5% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Cream</title>
          <description>The vehicle cream
Placebo: A placebo cream containing the same components as the vehicle for the active intervention arm</description>
        </group>
        <group group_id="E3">
          <title>SAN007 10% Cream</title>
          <description>A cream containing 10% East Indian Sandalwood Oil (EISO).
SAN007 10% cream: 10% EISO in a cream formulation applied twice a day for up to 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Castella</name_or_title>
      <organization>Santalis Pharmaceuticals</organization>
      <phone>2103992316 ext 101</phone>
      <email>paulc@satalispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

